https://scholars.lib.ntu.edu.tw/handle/123456789/609470
標題: | Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression | 作者: | Huang, Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi SHU-WEN LIN Ou, Shyh-Tyan YI-TING CHEN Chen, Ya-Wen Chang, Shu-Yuan Liu, Wen-Chun HSIN-YUN SUN CHIEN-CHING HUNG |
關鍵字: | Antiretroviral therapy; Mid-dose plasma concentration; Neuropsychiatric adverse effects; Non-nucleoside reverse transcriptase inhibitor; Switch therapy | 公開日期: | 十月-2021 | 卷: | 54 | 期: | 5 | 來源出版物: | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 摘要: | This study evaluated the efavirenz (EFV) mid-dose plasma concentration (C12), clinical efficacy, and safety after the switch to a single-tablet regimen containing tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and 400-mg EFV in virally suppressed HIV-positive Taiwanese who were receiving co-formulated TDF, emtricitabine (FTC), and 600-mg EFV. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/609470 | ISSN: | 16841182 | DOI: | 10.1016/j.jmii.2020.06.010 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。